---
title: "SGRY: Q2 2026 delivered revenue and EBITDA growth, with guidance reaffirmed and Idaho Falls divestiture boosting margins"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295401096.md"
description: "Q2 2026 saw 2.7% year-over-year revenue growth and a 14.7% adjusted EBITDA margin, with strong physician recruitment and reaffirmed full-year guidance. The Idaho Falls Market divestiture is expected to be accretive to EBITDA growth and reduces Medicaid exposure.Original document: Surgery Partners, Inc. [SGRY] Slides Release — Aug. 10 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-10T11:41:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295401096.md)
  - [en](https://longbridge.com/en/news/295401096.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295401096.md)
generator: "portal-rs"
---

# SGRY: Q2 2026 delivered revenue and EBITDA growth, with guidance reaffirmed and Idaho Falls divestiture boosting margins

Q2 2026 saw 2.7% year-over-year revenue growth and a 14.7% adjusted EBITDA margin, with strong physician recruitment and reaffirmed full-year guidance. The Idaho Falls Market divestiture is expected to be accretive to EBITDA growth and reduces Medicaid exposure.

Original document: Surgery Partners, Inc. \[SGRY\] Slides Release — Aug. 10 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [SGRY.US](https://longbridge.com/en/quote/SGRY.US.md)

## Related News & Research

- [Surgery Partners director Teresa DeLuca buys 10,000 shares worth $143,500](https://longbridge.com/en/news/296396198.md)
- [NORTHM: Q2 2026 saw lower revenue and EBITDA, but net profit surged on investment gains](https://longbridge.com/en/news/296623514.md)
- [AIIR: H1'26 saw resilient revenue and stable Adjusted EBITDA amid disruption, with growth set to accelerate](https://longbridge.com/en/news/296476265.md)
- [AMG: Q2 2026 saw 19% revenue growth and 30% EBITDA increase, led by Vanadium and Lithium](https://longbridge.com/en/news/296738095.md)
- [CLG: Strategic reset drove margin gains and major debt reduction, with FY27 EBITDA growth targeted](https://longbridge.com/en/news/296717409.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**